Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Drug Approvals Could Be Denied If Environmental Risks Not Properly Assessed

Executive Summary

As part of its revision of the EU medicines legislation, the European Commission is proposing tighter rules to reduce the environmental impact of medicines. Companies may want to start thinking now about whether their current environmental risk assessment processes would meet the likely new requirements.

You may also be interested in...

EU Legislative Reform: Environmental Risk Assessment Concerns Are Based On ‘Misunderstanding’

Reforms to better enforce environmental risk assessments are intended to ensure timely delivery of data, and should not thwart marketing authorization applications, according to a European Commission representative.

EU Partnership Offers Funding For Projects On Inclusive Clinical Trials, Synthetic Data & Theranostics

Europe’s public-private partnership, the Innovative Health Initiative, is seeking research projects in areas including innovative trial designs and methodologies to speed up the development of treatments for rare and ultra-rare conditions, reducing the environmental impact of health care products, and cutting the use of animals in drug safety testing.

Agreement On EU’s Radical Pharma Reform Plans ‘Could Take Three Years’

The controversial nature of some of the plans in the EU medicines legislative overhaul suggests a long road ahead for negotiations at the European Parliament and Council, with some “substantial amendments” likely along the way.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts